AC
LXEO icon

AXQ Capital’s Lexeo Therapeutics LXEO Stock Holding History

AXQ Capital’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,119
Closed -$150K – 1195
2026
Q1 		$150K Buy
+26,119
New +$185K 0.02% 807
2025
Q4 		– Sell
-14,921
Closed -$99.1K – 861
2025
Q3 		$99.1K Buy
14,921
+2,446
+20% +$11.8K 0.04% 518
2025
Q2 		$50.1K Buy
+12,475
New +$41K 0.02% 542

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

AXQ Capital's LXEO Position: Q2 2026 in Review

AXQ Capital sold out of Lexeo Therapeutics (LXEO) in Q2 2026, closing a stake of 26,119 shares — an estimated $150K sold.

AXQ Capital first reported a position in LXEO in Q2 2025 and held it in 3 quarters. The position peaked at $150K in Q1 2026. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • AXQ Capital reported no remaining Lexeo Therapeutics position as of Q2 2026 after selling out during the quarter.
  • AXQ Capital sold 26,119 Lexeo Therapeutics shares in Q2 2026, an estimated $150K.
  • AXQ Capital first reported a position in Lexeo Therapeutics in Q2 2025 and held it in 3 quarters.
  • AXQ Capital's Lexeo Therapeutics position peaked at $150K in Q1 2026.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.